文/西风 4月21日晚上，三博脑科医院管理集团股份有限公司（301293）公告：现收到内蒙古自 治区监察委员会签发关于公司控股股东、实际控制人之一暨董事长张阳先生 个人的《留置通知书》和《立案通知书》。张阳先生1965年10月出生，如今已近60岁，现任公司董事长，中国非公立医疗机构协会副会长、中国医院协会民营医 院管理分会副会长、北京市非公立医疗机构协会终身名誉会长。三博脑科2023年5月5日上市，上市未满2年，实控人兼董事长被留置、立案调查了！ 公司注册地北京市海淀区，主要从事以神经专科为特色的临床医疗服务，目前在北京、重庆、昆明、福建、成都和河南共运营了8家医院。 2022年、2023年、2024年，公司分别实现营业收入10.70亿元、13.13亿元、14.29亿元，扣非归母净利润分别为0.5207亿元、0.9360亿元、0.9431亿元。 | 财务指标 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | | --- | --- | --- | --- | --- | --- | | 审计意见 | | | 标准无保留意见 | ...

经济观察报记者张铃 2023年5月，三博脑科上市，目前，其总市值为93亿元。据三博脑科2024年年报，目前其共运营了8家医 院，分别位于北京、重庆、昆明、福建、成都和河南。三博脑科未在此次对张阳实施留置的内蒙古自治 区运营医院。 三博脑科上市后不久，张阳在接受经济观察报专访时提到，三博脑科不收患者红包，不靠药品耗材增加 收入，摒弃各种暗箱操作，每年拒收的红包数额达数百万元，同时给到医生高于公立医院的阳光收入。 2025年3月4日，三博脑科发布公告称，根据其经营发展及管理需要，张阳辞去总经理职务，仍担任董 事、董事长及董事会战略委员会主任委员职务。 4月21日晚，三博脑科（301293）(301293.SZ)公告称，其收到内蒙古自治区监察委员会签发的关于其控 股股东、实际控制人之一暨董事长张阳的个人《留置通知书》和《立案通知书》。 经济观察报记者致电张阳个人手机，显示已关机。他最新的朋友圈更新于4月16日，内容是他转发的家 乡某视频号对他的采访。 4月21日晚，三博脑科多名内部人士告诉经济观察报，他们是在看到公告后才知晓张阳被留置的消息， 他们对此消息感到意外。其中一名内部人士说："就在前两天，他还接受了央媒采 ...

A股医疗服务板块走低，三博脑科跌超12%，华南生物跌停，万邦医药跌超5%，澳洋健康、通策医疗等 跌幅居前。 ...

| 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | 道琼斯工业指 38170.41 | | -971.82 | -2.48% | | 纳斯达克指数 15870.90c | | -415.55 | -2.55% | | 标普500 | 5158.20 | -124.50 | -2.36% | 当地时间周一，美股全线下挫。截至收盘，道指跌2.48%，纳指跌2.55%，标普500指数跌2.36%。 个股方面，特斯拉跌5.8%。报道称，该电动汽车制造商平价版Model Y汽车的推出被推迟。 机构认为，当前是战略性看多的窗口期，短期回补缺口有待量能配合。 【财经日历】 2025全球汽车领袖闭门峰会举办 SPARK2025腾讯游戏发布会 | | | ►►中共中央、国务院印发《关于实施自由贸易试验区提升战略的意见》。其中提出： -支持符合条件的自由贸易试验区开展合格境外有限合伙人试点； -支持有条件的自由贸易试验区深化智能网联汽车道路测试、示范应用； -探索建立生物医药企业进口研发用物品"白名单"制度，允许免予办理进口药品通关单； ►►上交所召开私募机构座谈会。与会机构认为 ...

三博脑科(301293.SZ)公告称，公司收到内蒙古自治区监察委员会签发的关于公司控股股东、实际控制 人之一暨董事长张阳的个人《留置通知书》和《立案通知书》。目前，公司已对相关工作进行了妥善安 排，日常经营管理由高管团队负责，公司及子公司生产经营秩序正常。公司其他控股股东、实际控制人 及其他董事、监事和高级管理人员均正常履职，公司控制权未发生变化，董事会运作正常，上述事项不 会对公司日常生产经营产生重大影响。公司将持续关注后续进展情况，并严格按照相关规定及时履行信 息披露义务并提示相关风险。 ...

Core Viewpoint - The company, Sanbo Brain Science, is a leading private medical service group specializing in neurology, focusing on the integration of medical services, education, and research to enhance service quality and patient experience. Company Overview - Sanbo Brain Science operates eight hospitals across various regions in China, including five specialized neurology hospitals and three general hospitals, aiming to provide high-quality medical services [5][6]. - The company emphasizes a collaborative approach in medical, educational, and research fields, striving for continuous improvement in diagnostic and treatment technologies [5][6]. Business Development - In Q4 2024, the company integrated Chengdu Sanbo into its management system, further expanding its presence in the Southwest region [7]. - The company has successfully incorporated Luoyang Sanbo, enhancing its capabilities in neurology and obstetrics and gynecology, thereby strengthening its overall service offerings [7]. Industry Competition - Specialized hospitals are crucial in the healthcare system, contributing to advancements in medical technology and quality [8]. - Public hospitals dominate the neurosurgery sector in China, with notable institutions like Beijing Tiantan Hospital and Shanghai Huashan Hospital leading in academic reputation and resources. Sanbo Brain Science is positioned as the largest private neurology-focused medical service group in China, leveraging its experienced clinical team and advanced management practices to enhance its industry influence [8]. Financial and Operational Updates - The company has undergone several strategic acquisitions and capital increases to optimize its business structure and enhance operational efficiency, including the acquisition of 100% equity in Chongqing Xida and a 34% stake in Luoyang Sanbo [10][11]. - The company has also increased the registered capital of several subsidiaries to support their growth and operational needs, reflecting a commitment to long-term strategic goals [11].

证券代码：301293 证券简称：三博脑科 公告编号：2025-021 三博脑科医院管理集团股份有限公司 关于签署募集资金三方监管协议补充协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2023 年 5 月 23 日，三博脑科医院管理集团股份有限公司（以下简称"公司" 或"甲方"）与北京银行股份有限公司中关村分行（以下简称"乙方"）、中信 证券股份有限公司（以下简称"丙方"）签署了《募集资金三方监管协议》，具 体内容详见公司于 2023 年 5 月 24 日在巨潮资讯网（www.cninfo.com.cn）披露的 《关于开立募集资金专户并签署三方（四方）监管协议的公告》（公告编号： 2023-004）。为优化和改善募集资金使用时的审批程序，提高工作效率和募集资 金使用效率，现甲方、乙方、丙方共同签署了《募集资金三方监管协议补充协议》， 具体情况如下： （注：目前该账户尚有 5,000 万元募集资金用于现金管理状态。） 二、《募集资金三方监管协议补充协议》主要内容 经甲乙丙三方平等自愿、友好协商，对原《募集资金三方监管协议》的部分 条款进行调整，签署 ...

Market Performance - On April 17, 2025, the pharmaceutical sector had a change of +0.04%, outperforming the CSI 300 index by 0.06 percentage points, ranking 16th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, medical devices (+0.98%), pharmaceutical distribution (+0.40%), and offline pharmacies (+0.35%) performed well, while other bioproducts (-0.57%), vaccines (-0.48%), and blood products (-0.22%) lagged [1] - Top three gainers in individual stocks were Kangpeng Technology (+20.00%), Nuosige (+10.06%), and Yisheng Pharmaceutical (+10.03%); top three losers were Changyao Holdings (-6.33%), Hasanlian (-5.26%), and Shouyao Holdings (-4.81%) [1] Industry News - On April 17, 2025, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved statistically significant positive results in a key Phase III clinical trial (ACHIEVE-1) [2] - The study evaluated the safety and efficacy of Orforglipron compared to a placebo in adults with type 2 diabetes who had poor blood sugar control through diet and exercise alone [2] - Orforglipron is a research-based, once-daily oral small molecule (non-peptide) GLP-1 receptor agonist that can be taken at any time of the day without food and drink restrictions [2] Company News - Huayuan Bio (300401) reported Q1 2025 revenue of 326 million yuan, a year-on-year decrease of 1.18%, with net profit attributable to the parent company at 97 million yuan, a year-on-year increase of 5.50%, and a non-recurring net profit of 88 million yuan, up 44.42% year-on-year [3] - Puluo Pharmaceutical (000739) reported Q1 2025 revenue of 2.73 billion yuan, a year-on-year decrease of 14.63%, with net profit attributable to the parent company at 249 million yuan, a year-on-year increase of 1.98%, and a non-recurring net profit of 206 million yuan, down 14.05% year-on-year [3] - Sanbo Brain Science (301293) reported 2024 revenue of 1.43 billion yuan, a year-on-year increase of 8.84%, with net profit attributable to the parent company at 105 million yuan, a year-on-year increase of 34.24%, and a non-recurring net profit of 94 million yuan, up 0.77% year-on-year [3] - Betta Pharmaceuticals (300558) reported 2024 revenue of 2.89 billion yuan, a year-on-year increase of 17.74%, with net profit attributable to the parent company at 403 million yuan, a year-on-year increase of 15.67%, and a non-recurring net profit of 410 million yuan, up 55.92% year-on-year [3]

Group 1 - Sanbo Brain Science (301293.SZ) released its 2024 annual report on April 18, 2025, with 69 institutional investors holding a total of 54.79 million A-shares, accounting for 26.60% of the total share capital [1] - The top ten institutional investors include TBP 3Doctors (HK) Limited, various products from Taikang Life Insurance Co., Ltd., and others, with a combined holding ratio of 25.80%, which decreased by 5.34 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 61 new public funds were disclosed this period, including Southern CSI 1000 ETF and others, while one public fund, Dongcai Yuanjian Growth Mixed Initiation A, was no longer disclosed [2] - In the insurance capital sector, two insurance funds reduced their holdings compared to the previous quarter, while one new insurance investor was disclosed, namely Taikang Life Insurance Co., Ltd. - Dividend - Personal Dividend - 019L-FH002 [2]